logo
Plus   Neg
Share
Email

Eli Lilly Says Late-stage Study Of Baricitinib In Hospitalized Covid Patients Didn't Meet Main Goal

Eli Lilly and Company (LLY) and Incyte (INCY) on Thursday said their late-stage study of baricitinib in hospitalized Covid-19 patients did not achieve the main goal.

The phase III study dubbed Cov-Barrier of baricitinib plus standard of care (SoC) versus placebo plus SoC did not meet statistical significance on the primary endpoint. The main goal was defined as the difference in the proportion of participants progressing to the first occurrence of non-invasive ventilation including high flow oxygen or invasive mechanical ventilation including extracorporeal membrane oxygenation (ECMO) or death by Day 28.

The frequency of adverse events and serious adverse events were generally similar in the baricitinib and placebo groups, Eli Lilly said.

"While COV-BARRIER did not hit the primary endpoint based on stages of disease progression, the data show that baricitinib meaningfully reduced the risk of mortality above and beyond the recommended standard of care, without additional safety risks," said co-primary investigator E. Wesley Ely, professor of medicine and co-director of the Critical Illness, Brain Dysfunction, and Survivorship (CIBS) Center at Vanderbilt University Medical Center.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Nasdaq Inc. (NDAQ) reported Wednesday that its net income for the first quarter grew to $298 million or $1.78 per share from $203 million or $1.22 per share in the prior-year quarter. Excluding items, adjusted net income for the quarter was $327 million or $1.96 per share, compared to $251 million... Guan's Mushroom Co. is recalling all cases of its 200g/7.05-ounce packages of Enoki Mushroom citing the potential to be contaminated with Listeria monocytogenes, the U.S. Food and Drug Administration said. The recalled Enoki is a product of China and comes in a clear plastic package with the description "Enoki Mushroom" in English, Korean and French, and Guan's logo in the front. Shares of Roche were gaining around 2 percent in Swiss trading after the drug major reported Wednesday a 3 percent rise in first-quarter sales at constant currency basis mainly driven by strong growth in Diagnostics Division. Sales, on a reported basis, edged down 1 percent mainly with significant impact from biosimilars. Looking ahead for fiscal 2021, the company continues to expect sales to grow
Follow RTT